Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26370838
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26370838
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Immunotherapy
2015 ; 7
(11
): 1187-99
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Targeting B-cell maturation antigen in multiple myeloma
#MMPMID26370838
Tai YT
; Anderson KC
Immunotherapy
2015[]; 7
(11
): 1187-99
PMID26370838
show ga
Novel effective immunotherapies are needed for patients with multiple myeloma
(MM), since disease recurrence remains a major obstacle. B-cell maturation
antigen (BCMA), a cell surface protein universally expressed on malignant plasma
cells , has emerged as a very selective antigen to be targeted in novel
treatments for MM. We here first review BCMA-related biology, and then highlight
the recent clinical development of a novel afucosylated anti-BCMA monoclonal
antibody conjugated with monomethyl auristatin F via noncleavable linker
(GSK2857916). Chimeric antigen receptor-expressing T cells targeting BCMA may
also induce specific and durable anti-MM responses by patients' own effector
cells. Clinical trials testing these two approaches (NCT02064387, NCT02215967)
are currently ongoing in relapsed and refractory MM patients.
|*Immunotherapy
[MESH]
|Animals
[MESH]
|Antibodies, Monoclonal/chemistry/*therapeutic use
[MESH]